{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:57:34Z","timestamp":1765727854810},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>The prognostic role of high-sensitivity C-reactive protein (hsCRP) in acute heart failure is less well established than for chronic heart failure and the impact of its variation is unknown. We studied the impact of hsCRP variation in acute heart failure and whether it differed according to left ventricular function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analyzed patients prospectively included in an acute heart failure registry. Admission and discharge hsCRP were evaluated as part of the registry's protocol and its relative variation (\u0394hsCRP) was assessed. \u0394hsCRP during hospitalization\u200a=\u200a [(admission hsCRP\u200a\u2013\u200adischarge hsCRP)\/admission hsCRP]\u200a\u00d7\u200a100. Endpoint: all-cause death; follow-up: 3 years. A multivariate Cox-regression model was used to assess the prognostic value of \u0394hsCRP (continuous and categorical variable: cut-off 40% decrease); analysis was stratified according to ventricular function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We studied 439 patients: mean age 75 years, 50.1% men and 69.2% had heart failure with reduced ejection fraction (HFrEF). Median discharge hsCRP was 12.4\u200amg\/l and median \u0394hsCRP was \u223c40%. During follow-up 247 patients (56.3%) died: 73 (54.1%) heart failure with preserved ejection fraction (HFpEF) patients and 174 (57.2%) HFrEF patients. The multivariate-adjusted hazard ratio of 3-year mortality in HFpEF patients with hsCRP decrease of at least 40% during hospitalization was 0.56 (95% CI 0.32\u20130.99). A decrease of at least 40% in hsCRP was not mortality-associated in HFrEF patients. There was interaction between \u0394hsCRP and left ventricular ejection fraction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A decrease of at least 40% in hsCRP in acute heart failure was associated with a 44% decrease in 3-year death risk in HFpEF patients. No association between \u0394hsCRP and prognosis existed in HFrEF patients. Inflammation appears to play a different role according to left ventricular function.<\/jats:p>\n          <\/jats:sec>","DOI":"10.2459\/jcm.0000000000000726","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T19:34:33Z","timestamp":1541619273000},"page":"23-29","source":"Crossref","is-referenced-by-count":12,"title":["C-reactive protein decrease associates with mortality reduction only in heart failure with preserved ejection fraction"],"prefix":"10.2459","volume":"20","author":[{"given":"Patr\u00edcia","family":"Louren\u00e7o","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Medicina Interna"}]},{"given":"Joana","family":"Pereira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Medicina Interna"}]},{"given":"Ana","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Medicina Interna"}]},{"given":"Jo\u00e3o","family":"Ferreira-Coimbra","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Medicina Interna"}]},{"given":"Isaac","family":"Barroso","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar S\u00e3o Jo\u00e3o"}]},{"given":"Jo\u00e3o-Tiago","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar S\u00e3o Jo\u00e3o"},{"name":"Faculdade de Medicina da Universidade do Porto, Unidade I&D Cardiovascular do Porto"}]},{"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina da Universidade do Porto, Unidade I&D Cardiovascular do Porto"},{"name":"Servi\u00e7o de Cirurgia Cardiotor\u00e1cica, Centro Hospitalar S\u00e3o Jo\u00e3o"}]},{"given":"Paulo","family":"Bettencourt","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina da Universidade do Porto, Unidade I&D Cardiovascular do Porto"},{"name":"Servi\u00e7o de Medicina Interna, Hospital CUF Porto, Porto, Portugal"}]}],"member":"276","reference":[{"key":"R1-20230817","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.RES.0000043825.01705.1B","article-title":"Inflammatory mediators and the failing heart: past, present, and the foreseeable future","volume":"91","author":"Mann","year":"2002","journal-title":"Circ Res"},{"key":"R2-20230817","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10741-016-9533-z","article-title":"The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure","volume":"21","author":"Briasoulis","year":"2016","journal-title":"Heart Fail Rev"},{"key":"R3-20230817","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/BF02938356","article-title":"Role of inflammation in the progression of heart failure","volume":"9","author":"Yndestad","year":"2007","journal-title":"Curr Cardiol Rep"},{"key":"R4-20230817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medici.2015.12.001","article-title":"Clinical relevance of high sensitivity C-reactive protein in cardiology","volume":"52","author":"Adukauskiene","year":"2016","journal-title":"Medicina (Kaunas)"},{"key":"R5-20230817","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"R6-20230817","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14779072.2015.1000307","article-title":"Predicting therapeutic response in patients with heart failure: the story of C-reactive protein","volume":"13","author":"Huynh","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R7-20230817","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1385\/IR:24:2:163","article-title":"C-reactive protein, inflammation, and innate immunity","volume":"24","author":"Mortensen","year":"2001","journal-title":"Immunol Res"},{"key":"R8-20230817","doi-asserted-by":"crossref","first-page":"605810","DOI":"10.1155\/2014\/605810","article-title":"C-reactive protein: clinical and epidemiological perspectives","volume":"2014","author":"Salazar","year":"2014","journal-title":"Cardiol Res Pract"},{"key":"R9-20230817","first-page":"653045","article-title":"C-reactive protein: an in-depth look into structure, function, and regulation","volume":"2014","author":"Salazar","year":"2014","journal-title":"Int Sch Res Notices"},{"key":"R10-20230817","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/01.CIR.100.1.96","article-title":"C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?","volume":"100","author":"Lagrand","year":"1999","journal-title":"Circulation"},{"key":"R11-20230817","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cardfail.2008.10.030","article-title":"Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review","volume":"15","author":"Araujo","year":"2009","journal-title":"J Card Fail"},{"key":"R12-20230817","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijcard.2007.12.116","article-title":"C-reactive protein in chronic heart failure: a new predictor of survival","volume":"135","author":"Celik","year":"2009","journal-title":"Int J Cardiol"},{"key":"R13-20230817","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2003.11.021","article-title":"Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure","volume":"147","author":"Yin","year":"2004","journal-title":"Am Heart J"},{"key":"R14-20230817","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cardfail.2014.02.002","article-title":"High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-heart failure trial","volume":"20","author":"Kalogeropoulos","year":"2014","journal-title":"J Card Fail"},{"key":"R15-20230817","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1590\/S0066-782X2007000500014","article-title":"C-reactive protein: an inflammatory marker with prognostic value in patients with decompensated heart failure","volume":"88","author":"Villacorta","year":"2007","journal-title":"Arq Bras Cardiol"},{"key":"R16-20230817","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ejhf.104","article-title":"C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction","volume":"16","author":"Koller","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"R17-20230817","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijcard.2007.02.037","article-title":"Predictive value of high sensitivity CRP in patients with diastolic heart failure","volume":"125","author":"Michowitz","year":"2008","journal-title":"Int J Cardiol"},{"key":"R18-20230817","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1527-3466.2006.00033.x","article-title":"C-reactive protein (CRP)-lowering agents","volume":"24","author":"Prasad","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"R19-20230817","first-page":"400","article-title":"TSOC-HFrEF Registry: a registry of hospitalized patients with decompensated systolic heart failure: description of population and management","volume":"32","author":"Wang","year":"2016","journal-title":"Acta Cardiol Sin"},{"key":"R20-20230817","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"R21-20230817","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"R22-20230817","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"R23-20230817","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1042\/CS20050317","article-title":"Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support","volume":"110","author":"White","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"R24-20230817","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2007.05.061","article-title":"Inflammatory pathways in patients with heart failure and preserved ejection fraction","volume":"129","author":"Niethammer","year":"2008","journal-title":"Int J Cardiol"},{"key":"R25-20230817","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.4081\/hi.2011.e17","article-title":"Are there differences in acute phase inflammation markers regarding the type of heart failure?","volume":"6","author":"Sanchez-Lazaro","year":"2011","journal-title":"Heart Int"},{"key":"R26-20230817","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cyto.2009.11.006","article-title":"Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction","volume":"49","author":"Matsumoto","year":"2010","journal-title":"Cytokine"},{"key":"R27-20230817","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10741-010-9168-4","article-title":"Proinflammatory cytokines in heart failure: double-edged swords","volume":"15","author":"Hedayat","year":"2010","journal-title":"Heart Fail Rev"},{"key":"R28-20230817","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000330409","article-title":"Neurohormonal activation in acute heart failure: results from VERITAS","volume":"119","author":"Milo-Cotter","year":"2011","journal-title":"Cardiology"},{"key":"R29-20230817","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10741-013-9405-8","article-title":"Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target","volume":"19","author":"Glezeva","year":"2014","journal-title":"Heart Fail Rev"},{"key":"R30-20230817","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R31-20230817","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ejhf.1119","article-title":"Transcoronary concentration gradients of circulating microRNAs in heart failure","volume":"20","author":"De Rosa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R32-20230817","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.placenta.2017.01.128","article-title":"MicroRNA-34a targets regulator of calcineurin 1 to modulate endothelial inflammation after fetal cardiac bypass in goat placenta","volume":"51","author":"Yuan","year":"2017","journal-title":"Placenta"},{"key":"R33-20230817","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2459\/JCM.0b013e3282eee9a8","article-title":"The role of adiposity as a determinant of an inflammatory milieu","volume":"9","author":"Calabro","year":"2008","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R34-20230817","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01244665-201901000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T02:12:15Z","timestamp":1692324735000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01244665-201901000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2459\/jcm.0000000000000726","relation":{},"ISSN":["1558-2027","1558-2035"],"issn-type":[{"value":"1558-2027","type":"print"},{"value":"1558-2035","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}